share_log

HC Wainwright & Co. Maintains Buy on MEI Pharma, Lowers Price Target to $2

HC Wainwright & Co. Maintains Buy on MEI Pharma, Lowers Price Target to $2

HC Wainwright & Co.维持对MEI Pharma的买入,将目标价下调至2美元
Benzinga Real-time News ·  2023/02/13 06:18

HC Wainwright & Co. analyst Andrew Fein maintains MEI Pharma (NASDAQ:MEIP) with a Buy and lowers the price target from $5 to $2.

HC Wainwright&Co.分析师安德鲁·费恩维持纳斯达克(Meituan:MEIP)的买入评级,并将目标价从5美元下调至2美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发